Hepatitis E Virus, IgM BioAssay(TM) ELISA Kit (HEV)

Hepatitis resulting from infection with viruses other than Hepatitis A Virus (HAV) and Hepatitis B (HBV) virus was previously referred to as non-A, non-B hepatitis. The first characterised non-A, non-B hepatitis agent was that responsible for parentally transmitted non-A, non-B hepatitis, or what is now called Hepatitis C Virus. This was followed by the cloning of a portion of the fecal-orally-transmitted agent, the Hepatitis E Virus (HEV).\nHepatitis E Virus has been referred to as enterically transmitted non-A, non-B hepatitis. Epidemics of enterically transmitted Hepatitis E Virus have been recognised worldwide but \noccur principally in developing countries. They have been reported in Southeast Asia, central Asia, Africa, Mexico, and Central America. In these areas, contaminated water has been implicated as the principal vehicle of virus transmission. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 10-fold greater than that seen for HAV. Infection with HEV is particularly fatal for pregnant women, for whom the mortality rate can be as high as 10 to 20%. This HEV Antibody ELISA is an immunoassay, which employs synthetic and recombinant HEV antigens, for the detection of antibodies to HEV in human serum or plasma. These antigens, which correspond to the structure regions of HEV, constitute the solid phase antigenic adsorbent. Samples with O.D. values greater than or equal to the Cut-off value are defined as initially reactive. Initially reactive specimens are to be re-tested in duplicate. Samples, which do not react in either of the duplicate, repeat tests are considered non-reactive for antibodies to HEV. Samples, which are reactive in either of the duplicates tests, are considered repeatedly reactive.\n\nKit Components:\nH1927-03A: Microtiter Plate, pre-coated with HEV antigens, 1x96 wells \nH1927-03B: Pab (HRP) Conjugate, goat anti-human IgM antibody, 1x12ml \nH1927-03C: Non-Reactive Control, Inactivated normal human serum, 1x1ml\nH1927-03D: Reactive Control, Inactivated human serum, 1x1ml\nH1927-03E: Sample Buffer, Buffered solution with animal serum and preservative, 1x12ml \nH1927-03F: Wash Buffer (20X), 1x60ml\nH1927-03G: Substrate A, contains H2O2,1x10ml\nH1927-03H: Substrate B, contains TMB, 1x10ml\nH1927-03J: Stop Solution, 2N sulfuric acid (H2SO4), 1x14ml\n\nStorage and Stability:\nStore components at 4 degrees C except H1927-03C and H1927-03D. Store H1927-03C and H1927-03D at -20 degrees C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

H1927-03

Size

96Tests

Applications

ELISA

References

1. Aggarwal R, Krawczynski K. Hepatitis E: an overview and recent advances in clinical and laboratory research. J. Gastroenterol Hepatol (2000)15: 9-20. 2. Ruan B, Zhuang H, Ma Y. Dynamics of anti-HEV ORF2, ORT3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance. Chung Hua I Hsueh Tsa Chih (1998) 78: 498-500. 3. Riddell MA, Li F, Anderson DA. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J. Viral (2000) 74: 8011-8017. 4. Krawczynski K, Aggarwal R, Kamili S. Hepatitis E. Infect. Dis. Clin. North Am. (2000) 14: 669-687. 5. Li TC, Shinzawa H, etc. Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J Med Virol (2000) 62: 327-333.